| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
Azenta Reports Fourth Quarter and Full Year Results for Fiscal 2026, Ended September 30, 2026. |
| 30 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more
Azenta Announces Strategic Investments to Advance the Next Generation of GENEWIZ Gene Synthesis Capabilities Exclusive licensing agreement with Elegen and acquisition of SynPlexity strengthen gene synthesis capabilities, expand high-thro... |
| 07 Oct 2026 |
8-K: Costs Associated with Exit or Disposal Activities; Material Impairments
On October 5, 2026, the Board of Directors of Azenta, Inc. (the “Company”) approved, and the Company committed to, a restructuring plan (the “Plan”) within the Company’s Multiomics reportable segment. The Plan is intended primarily to co... |
| 17 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
As previously disclosed in the Company’s Current Report on Form 8-K filed on August 24, 2026, the Board of Directors (the “Board”) of Azenta, Inc. (the “Company”) appointed Dr. Martin D. Madaus as the Company’s Interim President and Chie... |
| 04 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Azenta Receives Full Repayment of $35 Million Vendor Loan Related to Sale of B Medical Systems BURLINGTON, Mass., September 4, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has received repayment in full, prior... |
| 24 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
AZENTA ANNOUNCES LEADERSHIP TRANSITION Current Director Dr. Martin Madaus Appointed Interim CEO Company Reaffirms Previously Announced Fourth Quarter Fiscal 2026 Total Revenue Guidance BURLINGTON, Mass., August 24, 2026 – Azenta, Inc. (N... |
| 11 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
azenta.com 200 Summit Drive 6th Floor Burlington, MA 01803 July 30, 2026 Erik Bello 135 Highgate Street Needham, MA 02492 Dear Erik, First, let me express my appreciation for the time and effort you have graciously provided us as we have... |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition
Azenta Reports Third Quarter Results for Fiscal 2026, Ended June 30, 2026. |
| 08 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +1 more
In accordance with Item 601(a)(6) of Regulation S-K, private information has been redacted as indicted in this exhibit. |
| 05 May 2026 |
8-K: Results of Operations and Financial Condition
Azenta Reports Second Quarter Results for Fiscal 2026, Ended March 31, 2026, Updates Full Year Fiscal 2026 Guidance, and Extends Long-Range Plan to 2029 |
| 07 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
On behalf of Azenta, Inc. (“Azenta” or the “Company”), I am pleased to offer you the position of Senior Vice President, President Multiomics pursuant to the terms and conditions set forth in this letter agreement (this “Agreement”). |
| 02 Apr 2026 |
8-K: Other Events
As previously disclosed in the Company’s Current Report on Form 8-K filed on December 29, 2025, Azenta Germany GmbH, a wholly owned subsidiary of Azenta, Inc. (the “Company”), entered into a definitive Sale and Purchase Agreement with Th... |
| 04 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
relating to the sale and purchase of the entire issued share capital of UK Biocentre Limited |
| 04 Feb 2026 |
8-K: Results of Operations and Financial Condition
BURLINGTON, Mass., February 4, 2026 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the first quarter ended December 31, 2025. |
| 02 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On January 29, 2026, Azenta, Inc. (the “Company”) was notified that Alan P. Malus resigned from the Company’s Board of Directors, effective January 29, 2026. Mr. Malus also served as a member of the Human Resources and Compensation Commi... |
| 29 Jan 2026 |
8-K: Submission of Matters to a Vote of Security Holders
The Annual Meeting of the stockholders of Azenta, Inc. (the “Company”) was held on January 28, 2026. The stockholders elected each of the Company’s nominees for director; approved, by a non-binding advisory vote, the overall compensation... |
| 29 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
In accordance with Item 601(a)(5) of Regulation S-K, the schedules to this exhibit, which are all listed in the Index, have been omitted. |
| 10 Dec 2025 |
8-K: Regulation FD Disclosure; Other Events
BURLINGTON, Mass., December 10, 2025 /PRNewswire/ --Azenta, Inc. (Nasdaq: AZTA) today announced that its Board of Directors has approved a share repurchase program under which the company may repurchase up to $250 million of its outstand... |
| 21 Nov 2025 |
8-K: Results of Operations and Financial Condition
Q4’25 reported revenue growth of 6% year over year and 4% on an organic basis |
| 05 Aug 2025 |
8-K: Results of Operations and Financial Condition
BURLINGTON, Mass., August 5, 2025 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2025. |
Loading...